Zacks: Harrow Health (NASDAQ:HROW) Given $11.38 Consensus Target Price by Brokerages

Shares of Harrow Health (NASDAQ:HROW) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus price target of $11.38 for the company and are anticipating that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given Harrow Health an industry rank of 83 out of 256 based on the ratings given to its competitors.

Several equities research analysts have commented on the company. TheStreet lowered ZTO Express (Cayman) from a “b+” rating to a “c” rating in a research note on Wednesday, May 1st. Zacks Investment Research cut HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Finally, ValuEngine upgraded YPF from a “sell” rating to a “hold” rating in a report on Monday, June 24th.

In other news, Director Robert J. Kammer sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $7.91, for a total transaction of $51,415.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.57, for a total value of $45,700.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,500 shares of company stock worth $154,915. Insiders own 12.43% of the company’s stock.

Several institutional investors have recently modified their holdings of HROW. FineMark National Bank & Trust acquired a new position in Harrow Health in the first quarter valued at approximately $113,000. EAM Global Investors LLC acquired a new position in Harrow Health in the first quarter valued at approximately $171,000. Institutional & Family Asset Management LLC acquired a new position in Harrow Health in the first quarter valued at approximately $195,000. Alambic Investment Management L.P. acquired a new position in Harrow Health in the first quarter valued at approximately $252,000. Finally, Corrado Advisors LLC acquired a new position in Harrow Health in the second quarter valued at approximately $475,000. Institutional investors and hedge funds own 32.08% of the company’s stock.

NASDAQ:HROW traded down $0.05 during trading hours on Friday, hitting $7.82. 174,671 shares of the stock were exchanged, compared to its average volume of 422,708. Harrow Health has a 52-week low of $2.22 and a 52-week high of $8.99. The business’s fifty day simple moving average is $7.01. The company has a current ratio of 3.43, a quick ratio of 3.22 and a debt-to-equity ratio of 0.47. The firm has a market cap of $194.42 million, a P/E ratio of 12.82 and a beta of 0.05.

Harrow Health (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.14). Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The firm had revenue of $12.29 million for the quarter, compared to analysts’ expectations of $12.10 million. As a group, sell-side analysts expect that Harrow Health will post -0.1 earnings per share for the current fiscal year.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

See Also: What impact do institutional investors have on markets?

Get a free copy of the Zacks research report on Harrow Health (HROW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.